Pfizer Launches 20-valent Pneumococcal Conjugate Vaccine (PCV20) in India, Offering Broad Protection Against Pneumococcal Disease

Pfizer has announced the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 20 — Valent (PCV20) for adults in India. The vaccine protects against more serotypes of pneumococcal disease than any other conjugate vaccine previously available in India. It helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease. The vaccine is available as a single shot and those vaccinated with PCV20 may not need a second dose.